Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ГБОУ ВПО Ставропольский государственный медицинский университет Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310; 2Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беэр-Шева
Список исп. литературыСкрыть список 1. Балакирева Е.Е. Лечебная тактика ведения больных с расстройствами пищевого поведения. Соврем. терапия в психиатрии и неврологии. 2013; 3–4: 23–5. / Balakireva E.E. Lechebnaia taktika vedeniia bol'nykh s rasstroistvami pishchevogo povedeniia. Sovrem. terapiia v psikhiatrii i nevrologii. 2013; 3–4: 23–5. [in Russian] 2. Глущенко В.В. Сравнительная эффективность пипофезина, тианептина и хлорпротиксена у пациентов с синдромом дефицита внимания и артериальной гипертензией: результаты открытого нерандомизированного исследования. Рацион. фармакотерапия в кардиологии. 2012; 3 (8): 447–52. / Glushchenko V.V. Sravnitel'naia effektivnost' pipofezina, tianeptina i khlorprotiksena u patsientov s sindromom defitsita vnimaniia i arterial'noi gipertenziei: rezul'taty otkrytogo nerandomizirovannogo issledovaniia. Ratsion. farmakoterapiia v kardiologii. 2012; 3 (8): 447–52. [in Russian] 3. Городничев А.В. Современные тенденции в терапии тревожных расстройств: от научных данных к клиническим рекомендациям. В кн.: Биологические методы терапии психических расстройств (доказательная медицина – клинической практике). Под ред. С.Н.Мосолова. М.: Социально-политическая мысль, 2012; с. 643–68. / Gorodnichev A.V. Sovremennye tendentsii v terapii trevozhnykh rasstroistv: ot nauchnykh dannykh k klinicheskim rekomendatsiiam. V kn.: Biologicheskie metody terapii psikhicheskikh rasstroistv (dokazatel'naia meditsina – klinicheskoi praktike). Pod red. S.N.Mosolova. M.: Sotsial'no-politicheskaia mysl', 2012; s. 643–68. [in Russian] 4. Губский Ю.И., Шаповалова В.А., Кутько И.И. и др. Лекарственные средства в психофармакологии. Киев–Харьков: Здоров’я–Торсiнг, 1997. / Gubskii Iu.I., Shapovalova V.A., Kut'ko I.I. i dr. Lekarstvennye sredstva v psikhofarmakologii. Kiev–Khar'kov: Zdorov’ia–Torsing, 1997. [in Russian] 5. Дробижев М.Ю. Труксал (Хлорпротиксен) при лечении больных в общесоматической сети. Психиатрия и психофармакотерапия. 2001; 3 (6): 215–6. / Drobizhev M.Iu. Truksal (Khlorprotiksen) pri lechenii bol'nykh v obshchesomaticheskoi seti. Psychiatry and Psychopharmacotherapy. 2001; 3 (6): 215–6. [in Russian] 6. Машковский М.Д. Лекарственные средства. 16-е изд., перераб., испр. и доп. М.: Новая волна, 2012. / Mashkovskii M.D. Lekarstvennye sredstva. 16-e izd., pererab., ispr. i dop. M.: Novaia volna, 2012. [in Russian] 7. Смирнова Л.В. Посттравматические стрессовые расстройства у военнослужащих (клиника, коморбидные состояния, факторы риска, терапия). Автореф. ... канд. мед. наук. Томск, 2003. / Smirnova L.V. Posttravmaticheskie stressovye rasstroistva u voennosluzhashchikh (klinika, komorbidnye sostoianiia, faktory riska, terapiia). Avtoref. ... kand. med. nauk. Tomsk, 2003. [in Russian] 8. Шмуклер А.Б. Применение Труксала (Хлорпротиксена) во внебольничной психиатрической практике. Психиатрия и психофармакотерапия. 2002; 4 (1): 38. / Shmukler A.B. Primenenie Truksala (Khlorprotiksena) vo vnebol'nichnoi psikhiatricheskoi praktike. Psychiatry and Psychopharmacotherapy. 2002; 4 (1): 38. [in Russian] 9. Яковлева О.Б. Использование Труксала у психически больных позднего возраста. Рус. мед. журн. 2001; 25: 1185–6. / Iakovleva O.B. Ispol'zovanie Truksala u psikhicheski bol'nykh pozdnego vozrasta. Rus. med. zhurn. 2001; 25: 1185–6. [in Russian] 10. Alapin B. [Treatment of depressive states with chlorprothixene]. [Article in Polish]. Pol Tyg Lek 1964; 19: 759–62. 11. Antkiewicz-Michaluk L. Action of antidepressant neuroleptics, chlorprothixene and levomepromazine, on the central noradrenergic system: comparison with other antidepressants. Pol J Pharmacol Pharm 1985; 37 (5): 673–83. 12. Antkiewicz-Michaluk L. The influence of chronic treatment with antidepressant neuroleptics on the central serotonin system. Pol J Pharmacol Pharm 1986; 38 (4): 359–70. 13. Brandsaeter B, Sabel M, Rui TO. [A woman with known anxiety, depression and alcohol abuse]. [Article in Norwegian]. Tidsskr Nor Laegeforen 2010; 130 (4): 385–6. 14. Bridler R, Häberle A, Müller ST et al. Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: A comparison with other psychiatric disorders. Eur Neuropsychopharmacol 2015; 25 (6): 763–72. 15. Brotto M. [Clinical evaluation of a new derivative of thioxanthene (Taractan)]. [Article in Italian]. Sist Nerv 1961; 13: 176–92. 16. Campanini T, De Risio C, Valla S. [Therapeutic results obtained with Taractan in depression]. [Article in Italian]. Riv Sper Freniatr Med Leg Alien Ment 1961; 85: 264–8. 17. Cazzullo CL. [The chemotherapy of anxiety]. Minerva Med 1965; 56: 1686–9. 18. Darling HF. Chlorprothixine (Taractan) and isocarboxazid (Marplan) in psychotic depressions. Am J Psychiatry 1961; 117: 931–2. 19. Eggers C. [Psychotropic drug therapy in children]. [Article in German]. Fortschr Med 1977 (a); 95 (33): 2028–33. 20. Eggers C. [Therapy of childhood schizophrenia]. [Article in German]. Schweiz Arch Neurol Neurochir Psychiatr 1977 (b); 120 (2): 205–15. 21. Felger HL. Depressed hospitalized psychiatric patients treated with chlorprothixene concentrate. J New Drugs 1965; 5 (4): 240–8. 22. Fracchia J, Sheppard C, Merlis S. Combination medications in psychiatric treatment: patterns in a group of elderly hospital patients. J Am Geriatr Soc 1971; 19 (4): 301–7. 23. Fynboe C, Christensen N, Halberg T et al. [Bromazepam (Lexotan) and chlorprothixene (Taractan) in psychoneurotic anxiety states. A randomized, double-blind study from general practice concerning the effect, drug consumption, and risk of repeated treatment]. [Article in Danish]. Ugeskr Laeger 1981; 143 (41): 2641–5. 24. Gardos G, Cole JO. A forgotten antipsychotic. Hosp Community Psychiatry 1990; 41 (11): 1261–2. 25. Gerlach J, Rasmussen PT, Hansen L et al. Antiparkinsonian agents and long-term neuroleptic treatment. Effect of G 31.406, orphenadrine, and placebo on parkinsonism, schizophrenic symptoms, depression and anxiety. Acta Psychiatr Scand 1977; 55 (4): 251–60. 26. Glusa E, Pertz HH. Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT(2B) receptors. Br J Pharmacol 2000; 130 (3): 692–8. 27. Gnat T, Walczak B, Wierzbicki T et al. [Preliminary results of chlorprothixene therapy of mental patients]. [Article in Polish]. Neurol Neurochir Psychiatr Pol 1963; 13: 103–6. 28. Górka Z, Janus K. Effects of neuroleptics displaying antidepressant activity on behavior of rats in the forced swimming test. Pharmacol Biochem Behav 1985; 23 (2): 203–6. 29. Grützner A. [Treatment of endogenous depression with psychopharmaceutics]. [Article in German]. Med Klin 1967; 62 (7): 241–5. 30. Hausner M, Dolezal V. Comparison of prothiadene and chorprotixene in neurtoic inpatients. Act Nerv Super (Praha) 1968; 10 (3): 298–9. 31. Hedlund PB. The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl) 2009; 206 (3): 345–54. 32. Hertrich O. [Ataractic treatment in psychiatry and general medicine. Overview of preparations, 3]. [Article in German]. Fortschr Med 1983; 101 (22): 1042–4. 33. Hussain MZ, Ahad A. Treatment of obsessive-compulsive neurosis. Can Med Assoc J 1970; 103 (6): 648 passim. 34. Hutchinson JT, Smedberg D. Treatment of depression: a comparative study of E.C.T. and six drugs. Br J Psychiatry 1963; 109: 536–8. 35. Jakóbczyk H. [Panic disorders of children: personal observation]. [Article in Polish]. Psychiatr Pol 1994; 28 (5): 557–66. 36. Kaartinen M. [Clinical experiences with chlorprothixene]. [Article in Swedish]. Nord Med 1962; 68: 1161–4. 37. Karabanov O. Clinical experience with chlorprothixene in psychiatric syndromes. Appl Ther 1963; 5: 133–6. 38. Kragh-Sørensen P, Holm P, Fynboe C et al. Bromazepam in generalized anxiety. Randomized, multi-practice comparisons with both chlorprothixene and placebo. Psychopharmacology (Berl) 1990; 100 (3): 383–6. 39. Kutschera E. [Treatment of restlessness and depressive conditions in children]. [Article in German]. Med Welt 1972; 23 (1): 39–40. 40. Laux G, Koenig W, Pfaff G. Antidepressant combination therapy of endogenous depressions with benzodiazepines or neuroleptics – a study comparing adjuvant treatment with oxazolam versus chlorprothixene. Pharmacopsychiatry 1988; 21 (2): 87–92. 41. Laux G, König W, Pfaff G et al. [Combined psychopharmacotherapy of endogenous depression. Adjuvant antidepressive drug treatment with benzodiazepines or neuroleptics: oxazolam versus chlorprothixene]. [Article in German]. Fortschr Med 1986; 104 (26): 511–6. 42. Mental Health Connection www.mhc.com 43. Navrátil J, Hrbek J, Komenda S. Experience with the treatment with chlorprothixen in senium. Act Nerv Super (Praha) 1973; 15 (2): 122–3. 44. Neyen H. [Chlorprothixene as an antipruuritc agent in dermatology]. [Article in German]. Med Welt 1963; 19: 1882–4. 45. Ostow M. Treating depression with tranquilizers: with dissenting view of lithium carbonate therapy. N Y State J Med 1975; 75 (5): 693–6. 46. Papp M, Moryl E, Willner P. Pharmacological validation of the chronic mild stress model of depression. Eur J Pharmacol 1996; 296 (2): 129–36. 47. Patch IC, Pitt BM, Yeo YM. The direct comparison of antidepressants: imipramine and chlorprothixene. J Psychiatr Res 1967; 5 (4): 273–80. 48. Petersen EN. Pre- and postsynaptic alpha-adrenoceptor antagonism by neuroleptics in vivo. Eur J Pharmacol 1981; 69 (4): 399–405. 49. Plevová J, Sochor K, Boleloucký Z. Sulpirid in patients hospitalized in an internal ward. Act Nerv Super (Praha) 1989; 31 (4): 269–70. 50. Poeldinger W. [Comparative clinical-psychiatric experiences with thiaxanthene-derivatives with special consideration of flupenthixol]. [Article in German]. Arzneimittelforschung 1967; 17 (9): 1133–5. 51. Poseł Z, Tomczak JW. [Treatment of depressive states and its role in prevention of drug dependence in adolescents]. [Article in Polish]. Psychiatr Pol 1979; 13 (6): 595–60. 52. Ravn J. The combined treatment of endogenous depression with imipramine (tofranil) and chlorprothixene (truxal), with special reference to ambulant therapy. Acta Psychiatr Scand Suppl 1961; 162: 168–78. 53. Ravn J, Kragh ER. [Treatment of manic patients with chlorprothixene (Truxal) in comparison with other treatment methods, with special reference to the duration of stabilization]. [Article in German]. Acta Psychiatr Scand 1963; 39 (Suppl. 169): 139. 54. Ravn J, Scharff A, Aaskoven O. [20 years experience with chlorprothixene (author’s transl)]. [Article in German]. Pharmakopsychiatr Neuropsychopharmakol 1980; 13 (1): 34–40. 55. Rimestad S. Clinical physiognomy of chlorprothixene and clopentixol. Acta Psychiatr Belg 1974; 74 (5): 491–9. 56. Roth BL, Craigo SC, Choudhary MS et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994; 268 (3): 1403–10. 57. Sirnes TB. [The most important psychopharmaca in general practice]. Tidsskr Nor Laegeforen 1964; 84: 281–3. 58. Tatsumi M, Jansen K, Blakely RD et al. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol 1999; 368 (2–3): 277–83. 59. Vencovsky E, Sedivec V, Peterova E et al. [Chlorprothixene in psychiatric work]. [Article in Czesh]. Cesk Psychiatr 1964; 60: 240–5. 60. Vetulani J. Adaptive changes as the mode of action of antidepressant treatments. Adv Biochem Psychopharmacol 1982; 31: 27–36. 61. Wander TJ, Nelson A, Okazaki H et al. Antagonism by neuroleptics of serotonin 5-HT1A and 5-HT2 receptors of normal human brain in vitro. Eur J Pharmacol 1987; 143 (2): 279–82. 62. Weidtmann W. [Somatotherapy of endogenous psychoses at Marburg university neurologic clinic]. [Article in German]. Psychiatr Neurol (Basel) 1964; 148: 218–35. 63. Zapletálek M., Kudrnová K., Preiningerová O et al. [Comparison of the therapeutic effect of bromazepam and chlorprothixene in depressive neuroses]. [Article in Czech]. Cesk Psychiatr 1982; 78 (6): 375–81.